Emerging role of circulating tumor cells in immunotherapy.
Rzhevskiy, A
Kapitannikova, A
Malinina, P
Volovetsky, A
Aboulkheyr Es, H
Kulasinghe, A
Thiery, JP
Maslennikova, A
Zvyagin, AV
Ebrahimi Warkiani, M
- Publisher:
- Ivyspring International Publisher
- Publication Type:
- Journal Article
- Citation:
- Theranostics, 2021, 11, (16), pp. 8057-8075
- Issue Date:
- 2021
Open Access
Copyright Clearance Process
- Recently Added
- In Progress
- Open Access
This item is open access.
Over the last few years, immunotherapy, in particular, immune checkpoint inhibitor therapy, has revolutionized the treatment of several types of cancer. At the same time, the uptake in clinical oncology has been slow owing to the high cost of treatment, associated toxicity profiles and variability of the response to treatment between patients. In response, personalized approaches based on predictive biomarkers have emerged as new tools for patient stratification to achieve effective immunotherapy. Recently, the enumeration and molecular analysis of circulating tumor cells (CTCs) have been highlighted as prognostic biomarkers for the management of cancer patients during chemotherapy and for targeted therapy in a personalized manner. The expression of immune checkpoints on CTCs has been reported in a number of solid tumor types and has provided new insight into cancer immunotherapy management. In this review, we discuss recent advances in the identification of immune checkpoints using CTCs and shed light on the potential applications of CTCs towards the identification of predictive biomarkers for immunotherapy.
Please use this identifier to cite or link to this item: